Universität zu Köln

Sureda, Anna, Andre, Marc, Borchmann, Peter, da Silva, Maria G., Gisselbrecht, Christian, Vassilakopoulos, Theodoros P., Zinzani, Pier Luigi and Walewski, Jan (2020). Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective. BMC Cancer, 20 (1). LONDON: BMC. ISSN 1471-2407

Full text not available from this repository.

Abstract

Autologous stem cell transplantation (ASCT) is a well-established approach to treatment of patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) recommended by both the European Society for Medical Oncology and the National Comprehensive Cancer Network based on the results from randomized controlled studies. However, a considerable number of patients who receive ASCT will progress/relapse and display suboptimal post-transplant outcomes. Over recent years, a number of different strategies have been assessed to improve post-ASCT outcomes and augment HL cure rates. These include use of pre- and post-ASCT salvage therapies and post-ASCT consolidative therapy, with the greatest benefits demonstrated by targeted therapies, such as brentuximab vedotin. However, adoption of these new approaches has been inconsistent across different centers and regions.In this article, we provide a European perspective on the available treatment options and likely future developments in the salvage and consolidation settings, with the aim to improve management of patients with HL who have a high risk of post-ASCT failure.ConclusionsWe conclude that early intervention with post-ASCT consolidation improves outcomes in patients with R/R HL who require ASCT. Future approvals of targeted agents are expected to further improve outcomes and provide additional treatment options in the coming age of personalized medicine.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Sureda, Anna UNSPECIFIED UNSPECIFIED UNSPECIFIED Andre, Marc UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED da Silva, Maria G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gisselbrecht, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Vassilakopoulos, Theodoros P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Zinzani, Pier Luigi UNSPECIFIED UNSPECIFIED UNSPECIFIED Walewski, Jan UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-311718
DOI:	10.1186/s12885-020-07561-2
Journal or Publication Title:	BMC Cancer
Volume:	20
Number:	1
Date:	2020
Publisher:	BMC
Place of Publication:	LONDON
ISSN:	1471-2407
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; BONE-MARROW-TRANSPLANTATION; QUALITY-OF-LIFE; BRENTUXIMAB VEDOTIN; SALVAGE THERAPY; PHASE-II; OPEN-LABEL; RADIATION-THERAPY; FOLLOW-UP Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/31171